FibroBiologics (FBLG) Common Equity (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Common Equity of $4.6 million for Q2 2026, up 439.07% year-over-year from $860000.0 in Q2 2025, and up 78.31% on a QoQ basis from $2.6 million in Q1 2026.
FibroBiologics (FBLG) Common Equity (2022 - 2026) Analysis & Trends
FibroBiologics has reported Common Equity for 5 years, with the latest figure at $4.6 million in Q2 2026.
- Common Equity for Q2 2026 came in at $4.6 million, up 439.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $4.6 million (up 439.07% YoY), and the FY2025 annual result was $6.2 million, up 125.08% from the prior year.
- Common Equity advanced to $4.6 million in Q2 2026, from $2.6 million in the prior quarter.
- Over five years, Common Equity peaked at $11.4 million in Q2 2023 and troughed at -$4.0 million in Q4 2022.
- A 5-year average of $2.4 million and a median of $2.4 million in 2025 frame the typical range for Common Equity.
- The widest annual swing landed in 2024, when Common Equity slumped 704.54%; it then soared 439.07% in 2026.
- A 5-year view of Common Equity shows it stood at -$4.0 million in 2022, then jumped by 131.36% to $1.3 million in 2023, then jumped by 118.28% to $2.7 million in 2024, then surged by 125.08% to $6.2 million in 2025, then fell by 24.69% to $4.6 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $4.6 million in Q2 2026, $2.6 million in Q1 2026, and $6.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | 4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.64 Mn |
| Mar 31, 2026 | 2.60 Mn |
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 860,000.00 |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | -2.39 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | 10.54 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 639,000.00 |
| Dec 31, 2022 | -4.00 Mn |